Turmeric Is therapeutic in vivo on patient-derived colorectal cancer xenografts: Inhibition of growth, metastasis, and tumor recurrence
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Colorectal cancer is the third most frequently diagnosed cancer worldwide. Clinically, chemotherapeutic agents such as FOLFOX are the mainstay of colorectal cancer treatment. However, the side effects including toxicity of FOLFOX stimulated the enthusiasm for developing adjuvants, which exhibit better safety profile. Turmeric extract (TE), which has been previously shown to suppress the growth of human and murine colon xenografts, was further demonstrated here for its inhibitory effects on colon cancer patient-derived xenografts (PDX). PDX models were successfully established from tissues of colon cancer patients and the PDX preserved the heterogeneous architecture through passages. NOD/SCID mice bearing PDX were treated either with TE or FOLFOX and differential responses toward these treatments were observed. The growth of PDX, metastasis and tumor recurrence in PDX-bearing mice were suppressed after TE treatments with 60% anti-tumor response rate and 83.3% anti-metastasis rate. Mechanistic studies showed that TE reduced tumor cell proliferation, induced cell apoptosis, inhibited metastasis via modulating multiple targets, such as molecules involved in Wnt and Src pathways, EMT and EGFR-related pathways. Nevertheless, FOLFOX treatments inhibited the PDX growth with sharp decreases of mice body weight and only mild anti-metastasis activities were observed. Furthermore, in order to have a better understanding of the underlying mechanisms, network pharmacology was utilized to predict potential targets and mechanism. In conclusion, the present study demonstrated for the first time that oral TE treatment was effective to suppress the growth of colon PDX and the recurrence of colon tumors in mice. The findings obtained from this clinically relevant PDX model would certainly provide valuable information for the potential clinical use of TE in colorectal cancer patients. The application of PDX model was well illustrated here as a good platform to verify the efficacy of multi-targeted herbal extracts.
著者Li MY, Yue GGL, Luo LX, Tsui SKW, Fung KP, Ng SSM, Lau CBS
期刊名稱Frontiers in Oncology
出版年份2021
月份1
卷號10
出版社FRONTIERS MEDIA SA
文章號碼574827
國際標準期刊號2234-943X
語言英式英語
關鍵詞colorectal cancer, patient-derived xenografts, turmeric, tumor recurrence, herbal medicines, network pharmacology
Web of Science 學科類別Oncology;Oncology

上次更新時間 2021-08-05 於 00:10